1. Home
  2. ELUT vs NXL Comparison

ELUT vs NXL Comparison

Compare ELUT & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elutia Inc.

ELUT

Elutia Inc.

N/A

Current Price

$0.95

Market Cap

23.3M

Sector

Health Care

ML Signal

N/A

Logo Nexalin Technology Inc.

NXL

Nexalin Technology Inc.

N/A

Current Price

$0.65

Market Cap

18.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ELUT
NXL
Founded
2015
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.3M
18.6M
IPO Year
2020
2022

Fundamental Metrics

Financial Performance
Metric
ELUT
NXL
Price
$0.95
$0.65
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$7.00
$5.00
AVG Volume (30 Days)
476.9K
200.0K
Earning Date
03-05-2026
03-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$21,746,000.00
$156,931.00
Revenue This Year
N/A
$38.28
Revenue Next Year
N/A
$185.71
P/E Ratio
N/A
N/A
Revenue Growth
24.08
N/A
52 Week Low
$0.50
$0.54
52 Week High
$3.46
$3.87

Technical Indicators

Market Signals
Indicator
ELUT
NXL
Relative Strength Index (RSI) 71.32 39.76
Support Level $0.74 $0.61
Resistance Level $0.91 $0.77
Average True Range (ATR) 0.09 0.06
MACD 0.03 0.01
Stochastic Oscillator 97.43 36.22

Price Performance

Historical Comparison
ELUT
NXL

About ELUT Elutia Inc.

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Share on Social Networks: